{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:47:10Z","timestamp":1783648030309,"version":"3.55.0"},"reference-count":84,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0207","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T22:10:07Z","timestamp":1753308607000},"page":"1-12","source":"Crossref","is-referenced-by-count":5,"title":["Recent progress in pathophysiology of cortisol-producing adrenal tumor"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7135-4434","authenticated-orcid":false,"given":"Toshihiko","family":"Yanase","sequence":"first","affiliation":[{"name":"Seiwakai Muta Hospital, Fukuoka 814-0163, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386: 913\u2013927.","DOI":"10.1016\/S0140-6736(14)61375-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, et al. (2016) Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 175: G1\u2013G34.","DOI":"10.1530\/EJE-16-0467"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Yanase T, Oki Y, Katabami T, Otsuki M, Kageyama K, et al. (2018) New diagnostic criteria of adrenal subclinical Cushing\u2019s syndrome: opinion from the Japan Endocrine Society. Endocr J 65: 383\u2013393.","DOI":"10.1507\/endocrj.EJ17-0456"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Pitsava G, Stratakis CA (2022) Genetic alterations in benign adrenal tumors. Biomedicines 10: 1041.","DOI":"10.3390\/biomedicines10051041"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Goto T, Takata T, Sato E, Tamura K, Yanase T (2013) A case of acute respiratory distress syndrome caused by cryptococcus and cytomegalovirus co-infection after Cushing\u2019s syndrome treatment. Kansensyogakuzassi 87: 39\u201343 (In Japanese).","DOI":"10.11150\/kansenshogakuzasshi.87.39"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, et al. (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4: 569\u2013576.","DOI":"10.1016\/S2213-8587(16)30005-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35: 101521.","DOI":"10.1016\/j.beem.2021.101521"},{"key":"8","unstructured":"8 Nawata H (1996) Cushing\u2019s syndrome (Adrenal). Annual report of the Ministry of Health and Welfare, Japan \u201cDisorders of adrenal hormones 1995\u201d: 234\u2013235 (In Japanese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526\u20131540.","DOI":"10.1210\/jc.2008-0125"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Katabami T, Asai S, Matsuba R, Sone M, Izawa S, et al. (2025) Changes in clinical features of adrenal Cushing syndrome: a national registry study. Endocr Connect 14: e240684.","DOI":"10.1530\/EC-24-0684"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, et al. (2020) Time to diagnosis in Cushing\u2019s syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab 105: dgz136.","DOI":"10.1210\/clinem\/dgz136"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, et al. (2015) From first symptoms to final diagnosis of Cushing\u2019s disease: experiences of 176 patients. Eur J Endocrinol 172: 285\u2013289.","DOI":"10.1530\/EJE-14-0766"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Limumpornpetch P, Morgan AW, Tiganescu A, Baxter PD, Nyawira Nyaga V, et al. (2022) The effect of endogenous Cushing syndrome on all-cause and cause-specific mortality. J Clin Endocrinol Metab 107: 2377\u20132388.","DOI":"10.1210\/clinem\/dgac265"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Loriaux DL (2017) Diagnosis and differential diagnosis of Cushing\u2019s syndrome. N Engl J Med 376: 1451\u20131459.","DOI":"10.1056\/NEJMra1505550"},{"key":"15","unstructured":"15 Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestation. Bull Johns Hopkins Hos 50: 173\u2013195."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Kelly W (1996) Exophthalmos in Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 45: 167\u2013170.","DOI":"10.1046\/j.1365-2265.1996.d01-1559.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Panzer SW, Patrinely JR, Wilson HK (1994) Exophthalmos and iatrogenic Cushing\u2019s syndrome. Ophthalmic Plast Reconstr Surg 10: 278\u2013282.","DOI":"10.1097\/00002341-199412000-00012"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Braun LT, Vogel F, Zopp S, Marchant Seiter T, Rubinstein G, et al. (2022) Whom should we screen for Cushing syndrome? The Endocrine Society Practice Guideline Recommendations 2008 Revisited. J Clin Endocrinol Metab 107: e3723\u2013e3730.","DOI":"10.1210\/clinem\/dgac379"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27: 193\u2013202.","DOI":"10.1291\/hypres.27.193"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Terzolo M, Reimondo G, Chiodini I, Castello R, Giordano R, et al. (2012) Screening of Cushing\u2019s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy. J Clin Endocrinol Metab 97: 3467\u20133475.","DOI":"10.1210\/jc.2012-1323"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Atar RV, Yildiz I, Topcu B, Elbuken G, Zuhur SS (2020) The frequency of Cushing\u2019s disease, ACTH-independent Cushing\u2019s syndrome and autonomous cortisol secretion among Turkish patients with obesity. North Clin Istanb 7: 214\u2013221.","DOI":"10.14744\/nci.2019.54771"},{"key":"22","unstructured":"22 Nawata H, Demura H, Suda T, Takayanagi R (1996) Adrenal preclinical Cushing\u2019s syndrome. Annual report of the Ministry of Health and Welfare \u201cDisorder of Adrenal Hormones 1995\u201d: 223\u2013226 (In Japanese)."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Akehi Y, Kawate H, Murase K, Nagaishi R, Nomiyama T, et al. (2013) Proposed diagnostic criteria for subclinical Cushing\u2019s syndrome associated with adrenal incidentaloma. Endocr J 60: 903\u2013912.","DOI":"10.1507\/endocrj.EJ12-0458"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Savoca C, et al. (2010) Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf) 73: 161\u2013166.","DOI":"10.1111\/j.1365-2265.2010.03794.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ichijo T, Ueshiba H, Nawata H, Yanase T (2020) A nationwide survey of adrenal incidentalomas in Japan: the first report of clinical and epidemiological features. Endocr J 67: 141\u2013152.","DOI":"10.1507\/endocrj.EJ18-0486"},{"key":"26","unstructured":"26 Yanase T, Fujieda K, Kajieda H, Tanahashi Y, Suzuki S (2011) A nationwide epidemiological study of Addison\u2019s disease and subclinical Cushing\u2019s disease. Annual report of Intractable Disease Research Grant of Ministry of Health, Labour and Welfare, Japan \u201cResearch on Adrenal Hormone Disorders 2010\u201d: 117\u2013124 (In Japanese)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, et al. (2014) Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab 99: 4462\u20134470.","DOI":"10.1210\/jc.2014-3007"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Favero V, Cremaschi A, Parazzoli C, Falchetti A, Gaudio A, et al. (2022) Pathophysiology of mild hypercortisolism: from the bench to the bedside. Int J Mol Sci 23: 673.","DOI":"10.3390\/ijms23020673"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Tabuchi Y, Otsuki M, Kasayama S, Kosugi K, Hashimoto K, et al. (2016) Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan. Endocr J 63: 29\u201335.","DOI":"10.1507\/endocrj.EJ15-0404"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Abe I, Sugimoto K, Miyajima T, Ide T, Minezaki M, et al. (2018) Clinical investigation of adrenal incidentalomas in Japanese patients of the Fukuoka region with updated diagnostic criteria for sub-clinical Cushing\u2019s syndrome. Intern Med 57: 2467\u20132472.","DOI":"10.2169\/internalmedicine.0550-17"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Aoe M, Okada A, Usui T, Manaka K, Nangaku M, et al. (2020) Comparison between the clinical characteristics of patients with adrenal incidentalomas and those with hypertension-associated adrenal tumors in a single center in Japan. Endocr J 67: 645\u2013654.","DOI":"10.1507\/endocrj.EJ19-0262"},{"key":"32","doi-asserted-by":"crossref","first-page":"e93136","DOI":"10.1172\/jci.insight.93136","volume":"2","author":"W Arlt","year":"2017","unstructured":"32 Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, et al. (2017) Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight 2: e93136.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33 Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, et al. (2019) High prevalence of diabetes in patients with Primary Aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: a large, multicenter cohort study in Japan. Diabetes Care 42: 938\u2013945.","DOI":"10.2337\/dc18-1293"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Yokomoto-Umakoshi M, Sakamoto R, Umakoshi H, Matsuda Y, Nagata H, et al. (2020) Unilateral primary aldosteronism as an independent risk factor for vertebral fracture. Clin Endocrinol (Oxf) 92: 206\u2013213.","DOI":"10.1111\/cen.14145"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Yokomoto-Umakoshi M, Fujita M, Umakoshi H, Ogasawara T, Iwahashi N, et al. (2025) Multiomics analysis unveils the cellular ecosystem with clinical relevance in aldosterone-producing adenomas with KCNJ5 mutations. Proc Natl Acad Sci U S A 122: e2421489122.","DOI":"10.1073\/pnas.2421489122"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Louiset E, Lefebvre H (2014) Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 370: 1071\u20131072.","DOI":"10.1056\/NEJMc1316140"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Cavalcante IP, Berthon A, Fragoso MC, Reincke M, Stratakis CA, et al. (2022) Primary bilateral macronodular adrenal hyperplasia: definitely a genetic disease. Nat Rev Endocrinol 18: 699\u2013711.","DOI":"10.1038\/s41574-022-00718-y"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Bertherat J, Bourdeau I, Bouys L, Chasseloup F, Kamenick\u00fd P, et al. (2023) Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia. Endocr Rev 44: 567\u2013628.","DOI":"10.1210\/endrev\/bnac034"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Assi\u00e9 G, Lib\u00e9 R, Espiard S, Rizk-Rabin M, Guimier A, et al. (2013) ARMC5 mutations in macronodular adrenal hyperplasia with Cushing\u2019s syndrome. N Engl J Med 369: 2105\u20132114.","DOI":"10.1056\/NEJMoa1304603"},{"key":"40","doi-asserted-by":"publisher","unstructured":"40 Chevalier B, Vantyghem MC, Espiard S (2021) Bilateral adrenal hyperplasia: pathogenesis and treatment. Biomedicines 9: 1397.","DOI":"10.3390\/biomedicines9101397"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Stratakis CA, Berthon A (2019) Molecular mechanisms of ARMC5 mutations in adrenal pathophysiology. Curr Opin Endocr Metab Res 8: 104\u2013111.","DOI":"10.1016\/j.coemr.2019.07.010"},{"key":"42","doi-asserted-by":"crossref","first-page":"e151390","DOI":"10.1172\/jci.insight.151390","volume":"7","author":"Y Okuno","year":"2022","unstructured":"42 Okuno Y, Fukuhara A, Otsuki M, Shimomura I (2022) ARMC5-CUL3 E3 ligase targets full-length SREBF in adrenocortical tumors. JCI Insight 7: e151390.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Chasseloup F, Bourdeau I, Tabarin A, Regazzo D, Dumontet C, et al. (2021) Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing\u2019s syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes Endocrinol 9: 813\u2013824.","DOI":"10.1016\/S2213-8587(21)00236-9"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Vaczlavik A, Bouys L, Violon F, Giannone G, Jouinot A, et al. (2022) KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genet Med 24: 374\u2013383.","DOI":"10.1016\/j.gim.2021.09.018"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Elhassan YS, Appenzeller S, Landwehr LS, Lippert J, Popat D, et al. (2024) Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation. Eur J Endocrinol 191: 334\u2013344.","DOI":"10.1093\/ejendo\/lvae106"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46 Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, et al. (2014) Recurrent somatic mutations underlie corticotropin-independent Cushing\u2019s syndrome. Science 344: 917\u2013920.","DOI":"10.1126\/science.1252328"},{"key":"47","doi-asserted-by":"publisher","unstructured":"47 Cao Y, He M, Gao Z, Peng Y, Li Y, et al. (2014) Activating hotspot L205R mutation in PRKACA and adrenal Cushing\u2019s syndrome. Science 344: 913\u2013917.","DOI":"10.1126\/science.1249480"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Beuschlein F, Fassnacht M, Assi\u00e9 G, Calebiro D, Stratakis CA, et al. (2014) Constitutive activation of PKA catalytic subunit in adrenal Cushing\u2019s syndrome. N Engl J Med 370: 1019\u20131028.","DOI":"10.1056\/NEJMoa1310359"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, et al. (2014) Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet 46: 613\u2013617.","DOI":"10.1038\/ng.2956"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, et al. (2014) Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing\u2019s syndrome: a European multicentric study. J Clin Endocrinol Metab 99: E2093\u2013E2100.","DOI":"10.1210\/jc.2014-2152"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, et al. (2014) Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [Rapid Communication]. Endocr J 61: 825\u2013832.","DOI":"10.1507\/endocrj.EJ14-0282"},{"key":"52","doi-asserted-by":"publisher","unstructured":"52 Higuchi S, Komai E, Fujimoto M, Tamura A, Shiga A, et al. (2015) Research on PRKACA mutation\/gene expression in 120 cases with SCS. Folia Endocrinologica Japonica 91 (Suppl. Update): 30\u201333 (In Japanese).","DOI":"10.1507\/endocrine.91.Suppl.Update_30"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Baba R, Oki K, Gomez-Sanchez CE, Otagaki Y, Itcho K, et al. (2021) Genotype-specific cortisol production associated with Cushing\u2019s syndrome adenoma with PRKACA mutations. Mol Cell Endocrinol 538: 111456.","DOI":"10.1016\/j.mce.2021.111456"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Rege J, Hoxie J, Liu CJ, Cash MN, Luther JM, et al. (2022) Targeted mutational analysis of cortisol-producing adenomas. J Clin Endocrinol Metab 107: e594\u2013e603.","DOI":"10.1210\/clinem\/dgab682"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Calebiro D, Hannawacker A, Lyga S, Bathon K, Zabel U, et al. (2014) PKA catalytic subunit mutations in adrenocortical Cushing\u2019s adenoma impair association with the regulatory subunit. Nat Commun 5: 5680.","DOI":"10.1038\/ncomms6680"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, et al. (2005) Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 65: 7622\u20137627.","DOI":"10.1158\/0008-5472.CAN-05-0593"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assi\u00e9 G, et al. (2016) Genetic landscape of sporadic unilateral adrenocortical adenomas without PRKACA p.Leu206Arg mutation. J Clin Endocrinol Metab 101: 3526\u20133538.","DOI":"10.1210\/jc.2016-1586"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, et al. (2011) Wnt\/\u03b2-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab 96: E419\u2013E426.","DOI":"10.1210\/jc.2010-1885"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Di Dalmazi G, Altieri B, Scholz C, Sbiera S, Luconi M, et al. (2020) RNA sequencing and somatic mutation status of adrenocortical tumors: novel pathogenetic insights. J Clin Endocrinol Metab 105: dgaa616.","DOI":"10.1530\/endoabs.70.YI3"},{"key":"60","unstructured":"60 Nawata H, Takayanagi R, Nakagawa H, Miura K (1999) Nation-wide epidemiological study of disorder of adrenal hormones. Annual report of the Ministry of Health and Welfare, Japan \u201cDisorders of adrenal hormones 1998\u201d: 11\u201355 (In Japanese)."},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, et al. (2019) Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med 171: 107\u2013116.","DOI":"10.7326\/M18-3630"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, et al. (2000) Subclinical Cushing\u2019s syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab 85: 1440\u20131448.","DOI":"10.1210\/jcem.85.4.6515"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, et al. (2010) Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J Clin Endocrinol Metab 95: 2736\u20132745.","DOI":"10.1210\/jc.2009-2387"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T (2001) The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf) 54: 797\u2013804.","DOI":"10.1046\/j.1365-2265.2001.01274.x"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Emral R, Uysal AR, Asik M, Gullu S, Corapcioglu D, et al. (2003) Prevalence of subclinical Cushing\u2019s syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 50: 399\u2013408.","DOI":"10.1507\/endocrj.50.399"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Lopez D, Luque-Fernandez MA, Steele A, Adler GK, Turchin A, et al. (2016) \u201cNonfunctional\u201d adrenal tumors and the risk for incident diabetes and cardiovascular outcomes: a cohort study. Ann Intern Med 165: 533\u2013542.","DOI":"10.7326\/M16-0547"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Fukumoto T, Umakoshi H, Iwahashi N, Ogasawara T, Yokomoto-Umakoshi M, et al. (2024) Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma. EBioMedicine 103: 105087.","DOI":"10.1016\/j.ebiom.2024.105087"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM (2022) Primary aldosteronism: state-of-the-art review. Am J Hypertens 35: 967\u2013988.","DOI":"10.1093\/ajh\/hpac079"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Youssef J, Novosad SA, Winthrop KL (2016) Infection risk and safety of corticosteroid use. Rheum Dis Clin North Am 42: 157\u2013176, ix\u2013x.","DOI":"10.1016\/j.rdc.2015.08.004"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Sieber SC, Dandurand R, Gelfman N, Iannini P, Braza F (1989) Three opportunistic infections associated with ectopic corticotropin syndrome. Arch Intern Med 149: 2589\u20132591.","DOI":"10.1001\/archinte.1989.00390110133029"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Kim DS, Park SK, Choi WH, Kim TW, Choi YY, et al. (2000) Pneumocystis carinii pneumonia associated with a rapid reduction of cortisol level in a patient with ectopic ACTH syndrome treated by octreotide and ketoconazole. Exp Clin Endocrinol Diabetes 108: 146\u2013150.","DOI":"10.1055\/s-2000-5810"},{"key":"72","unstructured":"72 Oosterhuis JK, van den Berg G, Monteban-Kooistra WE, Ligtenberg JJ, Tulleken JE, et al. (2007) Life-threatening Pneumocystis jiroveci pneumonia following treatment of severe Cushing\u2019s syndrome. Neth J Med 65: 215\u2013217."},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Arlt A, Harbeck B, Anlauf M, Alkatout I, Kl\u00f6ppel G, et al. (2008) Fatal pneumocystis jirovecii pneumonia in a case of ectopic Cushing\u2019s syndrome due to neuroendocrine carcinoma of the kidney. Exp Clin Endocrinol Diabetes 116: 515\u2013519.","DOI":"10.1055\/s-2008-1062729"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Gabalec F, Zavrelov\u00e1 A, Havel E, Cerman J Jr, Radocha J, et al. (2011) Pneumocystis pneumonia during medicamentous treatment of Cushing\u2019s syndrome\u2014a description of two cases. Acta Medica (Hradec Kralove) 54: 127\u2013130.","DOI":"10.14712\/18059694.2016.35"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 van Halem K, Vrolijk L, Pereira AM, de Boer MGJ (2017) Characteristics and mortality of Pneumocystis pneumonia in patients with Cushing\u2019s syndrome: a plea for timely initiation of chemoprophylaxis. Open Forum Infect Dis 4: ofx002.","DOI":"10.1093\/ofid\/ofx002"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76 Tan L, Zhao L, Tang G, Ren Y, Tian H, et al. (2023) Unexpected exacerbation of cryptococcal meningitis after unilateral adrenalectomy in a PMAH patient: a case report and literature review. BMC Endocr Disord 23: 199.","DOI":"10.1186\/s12902-023-01457-5"},{"key":"77","unstructured":"77 Tabuchi Y, Makio T, Nukino M, Goya K, Niki T, et al. (2019) A case of Cushing\u2019s syndrome in which metyrapone administration was associated with exacerbation of opportunistic infections. Folia Endocrinologica Japonica 95 (Suppl. Update): 87\u201389 (In Japanese)."},{"key":"78","unstructured":"78 Otsuki S, Ariyasu H, Sawabe N, Saito K, Kan C, et al. (2022) Two cases of immune reconstitution inflammatory syndrome with opportunistic infections after correction of hypercortisolism. Folia Endocrinologica Japonica 98: 391 (Abstract in Japanase)."},{"key":"79","doi-asserted-by":"crossref","unstructured":"79 Ohba D, Okamoto Y, Miyamoto U, Takeda Y, Terazaki Y, et al. (2023) Ectopic ACTH-producing pulmonary typical carcinoid with pneumocystic pneumonia after lobectomy: a case report. JJLC 63: 182\u2013187 (Abstract in English).","DOI":"10.2482\/haigan.63.182"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80 Brienze VMS, Andr\u00e9 JC, Liso E, Louis IV (2021) Cryptococcal immune reconstitution inflammatory syndrome: from blood and cerebrospinal fluid biomarkers to treatment approaches. Life (Basel) 11: 95.","DOI":"10.3390\/life11020095"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81 Shimatsu A, Biller BM, Fleseriu M, Pivonello R, Lee EJ, et al. (2024) Osilodrostat treatment in patients with Cushing\u2019s disease of Asian or non-Asian origin: a pooled analysis of two Phase III randomized trials (LINC 3 and LINC 4). Endocr J 71: 1103\u20131123.","DOI":"10.1507\/endocrj.EJ24-0153"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82 Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, et al. (2020) A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease. Endocr J 67: 841\u2013852.","DOI":"10.1507\/endocrj.EJ19-0617"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83 Igaz P, T\u00f6mb\u00f6l Z, Szab\u00f3 PM, Lik\u00f3 I, R\u00e1cz K (2008) Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem 15: 2734\u20132747.","DOI":"10.2174\/092986708786242921"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84 Detomas M, Altieri B, Deutschbein T, Fassnacht M, Dischinger U (2022) Metyrapone <i>versus<\/i> osilodrostat in the short-term therapy of endogenous Cushing\u2019s syndrome: results from a single center cohort study. Front Endocrinol (Lausanne) 13: 903545.","DOI":"10.3389\/fendo.2022.903545"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/1\/73_EJ25-0207\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:42:08Z","timestamp":1768016528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/1\/73_EJ25-0207\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0207","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0207"}}